Mesenchymal Stromal Cell-Derived Exosomes and Extracellular Vesicles Across Therapeutic Indications: A Structured Review of Published Preclinical and Early-Phase Clinical Study Designs, Administration Parameters, and Reported Outcomes
Author: Andrew J. Hillman (ORCID 0009-0001-5396-321X)
Published: 2026-07-05, Zenodo
DOI: 10.5281/zenodo.21209815
OpenAlex: W7167412972
License: CC BY 4.0
DOI: 10.5281/zenodo.21209814 (all versions). This version: 10.5281/zenodo.21209815.
Also on: Zenodo | Academia.edu | Podcast episode (Apple Podcasts) | PDF of this page

This structured review summarizes published preclinical and early-phase clinical studies of mesenchymal stromal cell exosomes and extracellular vesicles across therapeutic indications. It records study designs, administration parameters and reported outcomes, and attributes every result to the original authors. FDA has not approved any exosome or MSC-EV product, and human use requires an IND or BLA.
Exosome and mesenchymal stem cell-derived extracellular vesicle products are not approved by the FDA for any indication. This paper describes published scientific literature. It does not describe an available treatment.
Read the full paper at its permanent record: doi.org/10.5281/zenodo.21209815.
What do recent reviews say about MSC exosomes and extracellular vesicles?
What are MSC exosomes?
Are any exosome products FDA approved?
How do published studies report exosome dosing and administration?
Why do reviews of MSC-EV studies urge caution?
Listen: The Hillman Letter Podcast episode on this paper (Episode 6: What the Exosome Research Actually Shows: A Structured Review, Area by Area). MP3 of episode 6 (8 min 3 s) · Episode 6 on YouTube · Episode 6 on Apple Podcasts · Episode 6 on Pocket Casts · Episode 6 on Podcast Addict · Episode 6 on Podverse
Listen to The Hillman Letter Podcast: Apple Podcasts · Spotify · YouTube playlist · YouTube Music · Pocket Casts · Podcast Addict · Podcast Index · Podverse · Castamatic. About the author: Who is Andrew Jonathan Hillman.
Sources
- Witwer KW et al. Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications. J Extracell Vesicles. 2019. PMID 31069028
- Welsh JA et al. Minimal information for studies of extracellular vesicles (MISEV2023). J Extracell Vesicles. 2024. PMID 38326288
- Mizenko RR et al. A critical systematic review of extracellular vesicle clinical trials. J Extracell Vesicles. 2024. PMID 39330928
- Lener T et al. Applying extracellular vesicles based therapeutics in clinical trials, an ISEV position paper. J Extracell Vesicles. 2015. PMID 26725829
- FDA Public Safety Notification on Exosome Products, Dec 6, 2019
All publications · Andrew J. Hillman · Andrew Hillman, Dallas on LinkedIn · Book a meeting